1. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).
- Author
-
Kileel EM, Malvestutto CD, Lo J, Fitch KV, Fichtenbaum CJ, Aberg JA, Zanni MV, Martinez E, Okeke NL, Kumar P, Joao E, Bares SH, Berrner D, Smieja M, Roa JC, McCallum S, Douglas PS, Ribaudo HJ, and Grinspoon SK
- Subjects
- Humans, Body Mass Index, Drug Resistance, Viral, HIV Infections drug therapy, HIV Infections prevention & control, HIV Integrase Inhibitors therapeutic use, HIV Integrase Inhibitors pharmacology, HIV-1, HIV Integrase
- Abstract
Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m2/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years., Competing Interests: Potential conflicts of interest. C. D. M. reports institutional research grants from Lilly and personal fees from ViiV Healthcare and Gilead Sciences for participation in advisory board meetings outside the submitted work. J. L. reports consulting fees from ViiV Healthcare and Gilead Sciences, Inc, as well as investigator-initiated research grant support from ViiV Healthcare related to this work. C. J. F. reports grant support through their institution from Gilead Sciences, ViiV Healthcare, GSK, Janssen, AbbVie, Merck, Amgen, and Cytodyn, outside the submitted work; personal fees from Theratechnologies and ViiV Healthcare for consulting and participation on an advisory board unrelated to Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE); and a role as chair on the data and safety monitoring board (DSMB) for the Intrepid Study, outside the submitted work. J. A. A. reports institutional research support for clinical trials from Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, GSK, Janssen, Merck, Pfizer, Regeneron, and ViiV Healthcare; personal fees for participation on advisory boards from GSK/ViiV Healthcare and Merck; and participation on a DSMB from Kintor, all outside the submitted work. M. V. Z. reports grant support through their institution from NIH/NIAID and Gilead Sciences, Inc, relevant to the conduct of the study, as well as grants from NIH/NIAID and NIH/NHLBI, outside the submitted work; unpaid participation on a DSMB for NIH-funded studies; and support for meetings and/or travel from Conference on Retroviruses and Opportunistic Infections (CROI) and the International Workshop for HIV and Women from the conference organizing committee as an abstract reviewer and/or speaker. E. M. reports consulting fees and honoraria for lectures from Gilead Sciences, ViiV Healthcare, Janssen, and MSD; advisory board participation for ViiV Healthcare and MSD; and that their institution has received research grants from Gilead, Janssen, MSD, Theratechnologies, and ViiV Healthcare, unrelated to the submitted work. N. L. O. reports grants from NIH/NHLBI during the conduct of the study and consulting fees from Gilead Sciences unrelated to the submitted work. P. K. serves as a consultant and receives research funding from ViiV Healthcare, Merck, Theratechnologies, and Gilead and owns stock in Pfizer, Gilead, Merck, GSK, and Moderna. S. H. B. reports serving as a scientific advisor to Gilead Sciences including payment for expert testimony and research grants to their institution from Gilead Sciences, ViiV Healthcare, and Janssen unrelated to the submitted work. J. C. R. reports work supported by NIAID of the NIH. H. J. R. reports grants from NIH/NHLBI and Kowa Pharmaceuticals America, Inc, during the conduct of the study as well as grants from NIH/NIAID, NIH/NHLBI, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, and NIH/National Institute on Aging outside the submitted work. S. K. G. reports grants from NIH, Kowa Pharmaceuticals America, Inc, Gilead Sciences, and ViiV Healthcare during the conduct of the study; personal consulting fees from Theratechnologies, ViiV Healthcare, and Marathon Asset Management outside the submitted work; and participation on the Marathon Asset Management Scientific Advisory Board. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF